{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:09:03Z","timestamp":1748851743003,"version":"3.40.3"},"publisher-location":"Cham","reference-count":59,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030637484"},{"type":"electronic","value":"9783030637491"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-63749-1_5","type":"book-chapter","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T07:03:02Z","timestamp":1621580582000},"page":"47-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks"],"prefix":"10.1007","author":[{"given":"Friedhelm","family":"Meier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Harney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Rhiem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Neusser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Wasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Huster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dabrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita Katharina","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/0003-4819-144-6-200603210-00006","volume":"144","author":"K Anderson","year":"2006","unstructured":"Anderson K, Jacobson JS, Heitjan DF et al (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Int Med 144:397\u2013406. https:\/\/doi.org\/10.7326\/0003-4819-144-6-200603210-00006","journal-title":"Ann Int Med"},{"issue":"4","key":"5_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ajhg.2008.02.008","volume":"82","author":"AC Antoniou","year":"2008","unstructured":"Antoniou AC, Spurdle AB, Sinilnikova OM et al (2008) Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 82(4):937\u2013948. https:\/\/doi.org\/10.1016\/j.ajhg.2008.02.008","journal-title":"Am J Hum Genet"},{"key":"5_CR3","doi-asserted-by":"publisher","unstructured":"Balmana J, Sanz J, Bonfill X et al (2004) Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer 20:112(4):647\u2012652. https:\/\/doi.org\/10.1002\/ijc.20458","DOI":"10.1002\/ijc.20458"},{"key":"5_CR4","doi-asserted-by":"publisher","unstructured":"Bevers TB, Armstrong DK, Arun B et al (2010) Breast cancer risk reduction. J Natl Comp Canc Netw 8:1112\u20131146. https:\/\/doi.org\/10.6004\/jnccn.2015.0105","DOI":"10.6004\/jnccn.2015.0105"},{"key":"5_CR5","first-page":"63","volume-title":"Krankheitstheorien","author":"C Boorse","year":"2012","unstructured":"Boorse C (2012) Gesundheit als theoretischer Begriff. In: Schramme T (ed) Krankheitstheorien. Suhrkamp, Berlin, pp 63\u2013110"},{"key":"5_CR6","unstructured":"BSG 35:10\u201315"},{"key":"5_CR7","unstructured":"Clinical Trials for BRCA-P. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=brca-p. Accessed 8 May 2020"},{"issue":"1","key":"5_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/20502877.2016.1151253","volume":"22","author":"G Contino","year":"2016","unstructured":"Contino G (2016) The medicalization of health and shared responsibility. New Bioeth 22(1):45\u201355. https:\/\/doi.org\/10.1080\/20502877.2016.1151253","journal-title":"New Bioeth"},{"issue":"6","key":"5_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/cncr.27864","volume":"119","author":"JE Cott Chubiz","year":"2013","unstructured":"Cott Chubiz JE, Lee JM, Gilmore ME et al (2013) Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 119(6):1266\u20131276. https:\/\/doi.org\/10.1002\/cncr.27864","journal-title":"Cancer"},{"issue":"1","key":"5_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67\u201375. https:\/\/doi.org\/10.1016\/S1470-2045(14)71171-4","journal-title":"Lancet Oncol"},{"key":"5_CR11","unstructured":"Dabrock P (2012) Bef\u00e4higungsgerechtigkeit. Ein Grundkonzept konkreter Ethik in fundamentaltheologischer Perspektive. G\u00fctersloher Verlagshaus, G\u00fctersloh"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-3-658-11010-9_19","volume-title":"Soziologie von Gesundheit und Krankheit","author":"P Dabrock","year":"2016","unstructured":"Dabrock P (2016) Soziale Folgen der Biomarker-basierten und Big-Data-getriebenen Medizin. In: Hurrelmann K, Richter M (eds) Soziologie von Gesundheit und Krankheit. Springer, Berlin, pp 287\u2013300"},{"key":"5_CR13","doi-asserted-by":"publisher","unstructured":"de Bock GH, Vermeulen KM, Jansen L et al (2013) Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. Br J Cancer 108(8):1579\u201286. https:\/\/doi.org\/10.1038\/bjc.2013.149","DOI":"10.1038\/bjc.2013.149"},{"issue":"9","key":"5_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and morality. JAMA 304(9):967\u2013975. https:\/\/doi.org\/10.1001\/jama.2010.1237","journal-title":"JAMA"},{"key":"5_CR15","doi-asserted-by":"publisher","unstructured":"Easton DF, Pooley KA, Dunning AM et al (2007) Genomewide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087\u20131093. https:\/\/doi.org\/10.1038\/nature05887","DOI":"10.1038\/nature05887"},{"issue":"1","key":"5_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12885-018-4029-y","volume":"18","author":"C Engel","year":"2018","unstructured":"Engel C, Rhiem K, Hahnen E et al (2018) Prevalence of pathogenic BRCA1\/2 germline mutations among 802 women with unilateral triple-negative breast cancer without familial cancer history. BMC Cancer 18(1):265. https:\/\/doi.org\/10.1186\/s12885-018-4029-y","journal-title":"BMC Cancer"},{"issue":"5","key":"5_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","volume":"16","author":"DG Evans","year":"2014","unstructured":"Evans DG, Barwell J, Eccles DM et al (2014) The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 16(5):442. https:\/\/doi.org\/10.1186\/s13058-014-0442-6","journal-title":"Breast Cancer Res"},{"key":"5_CR18","unstructured":"FDA (1998). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/1998\/17970s39.pdf. Accessed 10 May 2020"},{"key":"5_CR19","doi-asserted-by":"publisher","unstructured":"Frost MH, Schaid DJ, Sellers TA et al (2000) Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284(3):319\u2012324. https:\/\/doi.org\/10.1001\/jama.284.3.319","DOI":"10.1001\/jama.284.3.319"},{"issue":"6","key":"5_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.breast.2010.05.003","volume":"19","author":"J Gahm","year":"2010","unstructured":"Gahm J, Wickman M, Brandberg Y (2010) Bilateral prophylactic mastectomy in women with inherited risk of breast cancer\u2013prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast 19(6):462\u2013469. https:\/\/doi.org\/10.1016\/j.breast.2010.05.003","journal-title":"Breast"},{"issue":"3","key":"5_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","volume":"125","author":"VR Grann","year":"2011","unstructured":"Grann VR, Patel PR, Jacobson JS et al (2011) Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers. Breast Cancer Res 125(3):837\u2013847. https:\/\/doi.org\/10.1007\/s10549-010-1043-4","journal-title":"Breast Cancer Res"},{"key":"5_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601792","author":"GL Griffith","year":"2004","unstructured":"Griffith GL, Edwards RT, Gray J (2004) Cancer genetics services: a systematic review of the economic evidence and issues. Br J Cancer. https:\/\/doi.org\/10.1038\/sj.bjc.6601792","journal-title":"Br J Cancer"},{"key":"5_CR23","doi-asserted-by":"publisher","unstructured":"Harter P, Hauke J, Heitz F et al (2017) Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One 12(10):e0186043. https:\/\/doi.org\/10.1371\/journal.pone.0186043","DOI":"10.1371\/journal.pone.0186043"},{"key":"5_CR24","first-page":"2695","volume":"37","author":"E Hauck","year":"2016","unstructured":"Hauck E (2016) Erkrankungsrisiko als Krankheit im Sinne der gesetzlichen Krankenversicherung? NJW 37:2695\u20132700s","journal-title":"NJW"},{"key":"5_CR25","doi-asserted-by":"publisher","unstructured":"Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, et al (2015) Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1\/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. JNCI J Natl Cancer Inst 107(5):djv033. https:\/\/doi.org\/10.1093\/jnci\/djv033","DOI":"10.1093\/jnci\/djv033"},{"key":"5_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24986","author":"K Hemminki","year":"2010","unstructured":"Hemminki K, M\u00fcller-Myshok B, Lichtner P et al (2010) Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.24986","journal-title":"Int J Cancer"},{"key":"5_CR27","doi-asserted-by":"publisher","unstructured":"Hood L (2013) Systems biology and P4 medicine: Past, present and future. Rambam Maimonides Med J 30:4(2):e0012. https:\/\/doi.org\/10.5041\/RMMJ.10112","DOI":"10.5041\/RMMJ.10112"},{"key":"5_CR28","unstructured":"Hruschka J (2014) Themenschwerpunkt: Grund und Grenzen der Solidarit\u00e4t in Recht und Ethik. In: Jahrbuch f\u00fcr Recht und Ethik 22. Duncker & Humblot, Berlin"},{"key":"5_CR29","doi-asserted-by":"crossref","unstructured":"Huster S, Harney A (2016) Anmerkung zu VG Darmstadt, Urt. v. 14.5.2015, Az.: 4 1 K 491\/13. DA, MedR 367, 369","DOI":"10.1007\/s00350-016-4287-0"},{"key":"5_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0908-4","author":"ME Jones","year":"2017","unstructured":"Jones ME, Schoemaker MJ, Wright LB et al (2017) Smoking and risk of breast cancer in the generations study cohort. Breast Cancer Res. https:\/\/doi.org\/10.1186\/s13058-017-0908-4","journal-title":"Breast Cancer Res"},{"key":"5_CR31","unstructured":"Kassen\u00e4rztlichen Bundesvereinigung (2020) Einheitlicher Bewertungsma\u00dfstab (EBM). https:\/\/www.kbv.de\/media\/sp\/EBM_Gesamt___Stand_1._Quartal_2020.pdf; Accessed 10 May 2020"},{"key":"5_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103672","author":"K Kast","year":"2016","unstructured":"Kast K, Rhiem K, Wappenschmidt B et al (2016) Prevalence of BRCA1\/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. https:\/\/doi.org\/10.1136\/jmedgenet-2015-103672","journal-title":"J Med Genet"},{"key":"5_CR33","unstructured":"Kettner M (2018) Einheit und Differenz von kurativer und wunscherf\u00fcllender Medizin. In: Ringkamp\/Wittwer (ed) Was ist Medizin? Verlag Karl Alber, Freiburg\/M\u00fcnchen, pp 19\u201341"},{"key":"5_CR34","doi-asserted-by":"crossref","unstructured":"King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA 286(18):2251\u20132256. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/1108388","DOI":"10.1001\/jama.286.18.2251"},{"key":"5_CR35","unstructured":"Krebs in Deutschland (2015) Eine gemeinsame Ver\u00f6ffentlichung des Robert Koch-Institut (ed) und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. 10. Ausgabe, 2015.  https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2015\/krebs_in_deutschland_2015.pdf;jsessionid=AAFA4585AE4BD2B35F2FC3351EE49072.1_cid381?__blob=publicationFile. Accessed 10 May 2020"},{"key":"5_CR36","doi-asserted-by":"publisher","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes et al (2017) Genomewide association study identifies novel breast cancer susceptibility loci. Nature. risks of breast, ovarian, and contrallateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. https:\/\/doi.org\/10.1001\/jama.2017.7112","DOI":"10.1001\/jama.2017.7112"},{"key":"5_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182783c2f","author":"JS Kwon","year":"2013","unstructured":"Kwon JS, Tinker A, Pansegrau G et al (2013) Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. https:\/\/doi.org\/10.1097\/AOG.0b013e3182783c2f","journal-title":"Obstet Gynecol"},{"key":"5_CR38","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF Registernummer: 032-045OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/. Accessed 11 May 2020"},{"issue":"1","key":"5_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/1096-8628(20010101)98:1<15::AID-AJMG1014>3.0.CO;2-0","volume":"98","author":"L Lodder","year":"2001","unstructured":"Lodder L, Frets PG, Trijsburg RW et al (2001) Psychological impact of receiving a BRCA1\/BRCA2 test result. Am J Med Genet 98(1):15\u201324","journal-title":"Am J Med Genet"},{"key":"5_CR40","doi-asserted-by":"publisher","unstructured":"Lostumbo L, Carbine NE, Wallace J (2010 Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database. Syst Rev. https:\/\/doi.org\/10.1002\/14651858","DOI":"10.1002\/14651858"},{"issue":"1","key":"5_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-020-1247-4","volume":"22","author":"N Mavaddat","year":"2020","unstructured":"Mavaddat N, Antoniou AC, Mooij TM et al (2020) Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 22(1):8. https:\/\/doi.org\/10.1186\/s13058-020-1247-4","journal-title":"Breast Cancer Res"},{"key":"5_CR42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-10986","author":"F Meier","year":"2017","unstructured":"Meier F, Ried J, Braun M et al (2017) \u2018Healthy sick\u2019 oder: Wie genetisches Risiko den Krankheitsbegriff des GKV-Systems aushebelt. Gesundheitswesen. https:\/\/doi.org\/10.1055\/s-0043-10986","journal-title":"Gesundheitswesen"},{"key":"5_CR43","unstructured":"Meier F Harney A, Rhiem et al (2018) \u2018Risikoadaptierte Pr\u00e4vention\u2019 . Governance Perspective f\u00fcr Leistungsanspr\u00fcche bei genetischen (Brustkrebs-)Risiken. Springer, Wiesbaden. https:\/\/www.springer.com\/de\/book\/9783658208004"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/ng.569","volume":"42","author":"A Meindl","year":"2010","unstructured":"Meindl A, Hellebrand H, Wiek C et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42:410\u2013414. https:\/\/doi.org\/10.1038\/ng.569","journal-title":"Nat Genet"},{"issue":"19","key":"5_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3238\/arztebl.2011.0323","volume":"108","author":"A Meindl","year":"2011","unstructured":"Meindl A, Ditsch N, Kast K et al (2011) Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch \u00c4rztebl 108(19):323\u2013330. https:\/\/doi.org\/10.3238\/arztebl.2011.0323","journal-title":"Dtsch \u00c4rztebl"},{"key":"5_CR46","unstructured":"Nationaler Krebsplan. Handlungsfelder, Ziele und Umsetzungsempfehlungen, Brosch\u00fcre des Bundesgesundheitsministeriums, Stand 2012. https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/5_Publikationen\/Praevention\/Broschueren\/Broschuere_Nationaler_Krebsplan_-_Handlungsfelder__Ziele_und_Umsetzungsempfehlungen.pdf. Accessed 11 May 2020"},{"key":"5_CR47","doi-asserted-by":"publisher","unstructured":"Neusser S, Lux B, Barth C et al (2019) The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance. Curr Med Res Opin 35(12):2103\u20132110. https:\/\/doi.org\/10.1080\/03007995.2019.1654689","DOI":"10.1080\/03007995.2019.1654689"},{"issue":"8","key":"5_CR48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan E, Vaillant F, Branstetter D et al (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22(8):933\u2013939. https:\/\/doi.org\/10.1038\/nm.4118","journal-title":"Nat Med"},{"issue":"3","key":"5_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/tbj.13257","volume":"25","author":"K Rhiem","year":"2019","unstructured":"Rhiem K, B\u00fccker-Nott HJ, Hellmich M et al (2019) Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort. Breast J 25(3):455\u2013460. https:\/\/doi.org\/10.1111\/tbj.13257","journal-title":"Breast J"},{"key":"5_CR50","doi-asserted-by":"crossref","unstructured":"Schnell M (2017) Ethik im Zeichen vulnerabler Personen. Leiblichkeit \u2013 Endlichkeit \u2013 Nichtexklusivit\u00e4t. Velbr\u00fcck Wissenschaft, Weilerswist","DOI":"10.5771\/9783845292557"},{"key":"5_CR51","doi-asserted-by":"publisher","unstructured":"Sch\u00f6ne-Seifert B, Friedrich DR, Harney A et al (2018) Medizinische Notwendigkeit: Herausforderungen eines unscharfen Begriffs. Ethik Med. 325\u2013341. https:\/\/doi.org\/10.1007\/s00481-018-0497-5","DOI":"10.1007\/s00481-018-0497-5"},{"key":"5_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2017.02.008","author":"MG Schrauder","year":"2017","unstructured":"Schrauder MG, Brunel-Geuder L, H\u00e4berle L et al (2017) Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Breast. https:\/\/doi.org\/10.1016\/j.breast.2017.02.008","journal-title":"Breast"},{"key":"5_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv590","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A et al (2016) Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdv590","journal-title":"Ann Oncol"},{"key":"5_CR54","unstructured":"Wassermann K, Dick J, Schmutzler RK, et al (2017) Impact of distress and personality factors on preference for preventive strategies in BRCA1\/2 mutation carriers: Results of a prospective cohort study. Germany acknowledgment of research support: grant no. IIA5-2512 FSB 002 (German Federal Ministry of Health). Submitted to Cancer"},{"key":"5_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-658-02239-6","volume-title":"Krankenversicherung oder Gesundheitsvorsorge. Gesundheitssysteme im Vergleich","author":"C Wendt","year":"2013","unstructured":"Wendt C (2013) Krankenversicherung oder Gesundheitsvorsorge. Gesundheitssysteme im Vergleich. Springer, Wiesbaden"},{"key":"5_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4116","author":"J Wise","year":"2013","unstructured":"Wise J (2013) NICE recommends preventive drugs for breast cancer. BMJ. https:\/\/doi.org\/10.1136\/bmj.f4116","journal-title":"BMJ"},{"issue":"1","key":"5_CR57","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/j.clbc.2018.09.011","volume":"19","author":"YL Xiao","year":"2019","unstructured":"Xiao YL, Wang K, Liu Q et al (2019) Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review. Clin Breast Cancer 19(1):e48\u2013e65. https:\/\/doi.org\/10.1016\/j.clbc.2018.09.011","journal-title":"Clin Breast Cancer"},{"key":"5_CR58","unstructured":"ZEKO Priorisierung medizinischer Leistungen im System der Gesetzlichen Krankenversicherung (GKV) Langfassung 2007. https:\/\/www.zentrale-ethikkommission.de\/downloads\/langfassungpriorisierung.pdf. Accessed 11 May 2020"},{"issue":"10","key":"5_CR59","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/cncr.11757","volume":"98","author":"SM Zion","year":"2003","unstructured":"Zion SM, Slezak JM, Sellers TA et al (2003) Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer 98(10):2152\u20132160. https:\/\/doi.org\/10.1002\/cncr.11757","journal-title":"Cancer"}],"container-title":["Recent Results in Cancer Research","Ethical Challenges in Cancer Diagnosis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-63749-1_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T07:04:08Z","timestamp":1621580648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-63749-1_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030637484","9783030637491"],"references-count":59,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-63749-1_5","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"type":"print","value":"0080-0015"},{"type":"electronic","value":"2197-6767"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"22 May 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}